Femasys (NASDAQ:FEMY) & Pro-Dex (NASDAQ:PDEX) Head to Head Review

Femasys (NASDAQ:FEMY) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Institutional & Insider Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 12.3% of Femasys shares are owned by insiders. Comparatively, 47.5% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Femasys and Pro-Dex”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.07 million	22.47	-$14.25 million	($0.81)	-1.30
Pro-Dex	$53.84 million	2.83	$2.13 million	$1.54	30.36

Pro-Dex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Femasys and Pro-Dex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,435.77%	-141.49%	-82.30%
Pro-Dex	9.17%	16.74%	9.98%

Volatility & Risk

Femasys has a beta of -2.83, meaning that its share price is 383% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Femasys and Pro-Dex, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	3	0	3.00
Pro-Dex	0	0	1	0	3.00

Femasys currently has a consensus price target of $10.00, indicating a potential upside of 852.38%. Pro-Dex has a consensus price target of $52.00, indicating a potential upside of 11.23%. Given Femasys’ higher probable upside, research analysts clearly believe Femasys is more favorable than Pro-Dex.

Summary

Pro-Dex beats Femasys on 9 of the 13 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Pro-Dex

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.